The UCL TAS Fund aims to accelerate the transition from discovery science to the early stages of therapeutic development, by providing funding, guidance and support to overcome hurdles in progression to clinical practice.
In its inaugural call, 10 individual project proposals (from 21 received) were each awarded TAS funding of up to £75,000 for up to 12 months. Dr John Counsell led the successful bid for a study entitled “Validating the safety and efficacy of novel lentiviral vector technology in stem cell therapy for Duchenne Muscular Dystrophy (DMD)”.
DMD is a severe muscle-wasting disease for which there is currently no cure. It is caused by errors in the dystrophin gene which affects production of an essential muscle protein. Dr Counsell’s project aims to use improved vectors to deliver functional versions of the dystrophin gene into the cells of affected patients and would potentially provide a best in class therapy. Having demonstrated proof-of-concept in a recent publication the TAS Panel agreed that the potential to validate a novel therapeutic platform, and thereby pursue a relatively quick and well-defined path into the clinic for DMD, is very appealing.
Managed by the Translation Research Office (TRO), the TAS fund is supported by the MRC, the Wellcome Trust and the three National Institute for Health Research (NIHR) Biomedical Research Centres (BRCs) affiliated with UCL - including the NIHR GOSH BRC.